Table 2.
Best Objective Response According to mRECIST.
| TACE + lenvatinib + PD-1 inhibitors (n = 23) | TACE + lenvatinib (n = 32) | TACE + sorafenib (n = 29) | P-value | |
|---|---|---|---|---|
| Complete response | 1 (4.35) | 1 (3.13) | 0 (0.00) | |
| Partial response | 19 (82.61) | 14 (43.75) | 10 (34.48) | |
| Stable disease | 3 (13.04) | 9 (28.13) | 4 (13.79) | |
| Progressive disease | 0 (0.00) | 8 (25.00) | 15 (51.72) | |
| ORR | 20 (86.96) | 15 (46.88) | 10 (34.48) | .0005 |
| Disease control rate | 23 (100) | 24 (75) | 14 (48.28) | .0002 |
Abbreviations: mRECIST, modified response evaluation criteria in solid tumors; PD-1, programmed death 1; TACE, transarterial chemoembolization; ORR, objective response rate.